Legend Biotech Surges 42% on In Vivo CAR-T Data

Speculative capital is rotating hard into targeted oncology names right now, and Legend Biotech Corporation (NASDAQ: LEGN) is at the center of it.

Shares closed Tuesday up 42.22%, confirming what early movers already knew: the Phase 1 data for LB2501 was not incremental. It was a category-level result.

What the Data Actually Shows

Legend announced preliminary Phase 1 clinical data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T therapy, ahead of its late-breaking oral presentation at the European Hematology Association (EHA) 2026 Congress in Stockholm, scheduled for June 14. The trial enrolled 12 patients with relapsed or refractory B-cell non-Hodgkin lymphoma across two dose cohorts. At dose level 2, the objective response rate came in at 100% (6/6), with a complete response rate of 83.3% (5/6). All responses were ongoing at the data cutoff. CAR-T cells were detected in peripheral blood for up to 116 days, consistent with durable in vivo expansion. Critically, no dose-limiting toxicities, no serious adverse events, and no cases of ICANS were reported. Infusion-related reactions and cytokine release syndrome occurred in 75% and 66.7% of patients respectively, all at or below Grade 2.

This is where it gets interesting: LB2501 is designed to generate CAR-T cells directly within the patient following a single intravenous infusion, eliminating the need for traditional cell manufacturing and lymphodepleting chemotherapy. If that approach holds up at scale, the access and cost structure implications for CAR-T broadly are significant.

The Commercial Backdrop

The LB2501 data did not arrive in isolation. Just one day earlier at ASCO 2026, Legend also presented first-in-human Phase 1 results for LB2102, its DLL3-targeted CAR-T for relapsed or refractory small cell lung cancer and large-cell neuroendocrine carcinoma. At higher dose levels, LB2102 posted an ORR of 28.6% and a disease control rate of 78.6% in heavily pretreated solid tumor patients. That is a meaningful early signal in a notoriously resistant tumor type. Combined with updated CARVYKTI data reinforcing durable efficacy in multiple myeloma, the two-day conference output represented a pipeline-wide inflection point for the company.

Commercially, CARVYKTI continues to scale. Q1 2026 net trade sales reached approximately $597 million, up 62% year-over-year, with the therapy now available across 18 global markets. Full-year 2025 CARVYKTI sales hit $1.9 billion, and management has guided toward a 2026 consensus forecast of approximately $2.9 billion. The company narrowed its net loss to $54.3 million in Q1 2026, down from $101.0 million a year prior, with cash and time deposits of $834.6 million as of March 31, 2026.

Analyst Positioning and Price Targets

Prior to Tuesday’s move, the analyst community was split. RBC Capital held an Outperform rating with a $64 price target following Q1 results. Morgan Stanley maintained an Overweight rating with a $49 target. HC Wainwright held a $50 target as of May 18. TD Cowen, which downgraded the stock to Hold in January following a Q4 revenue miss, had a $29 target. The consensus across 21 analysts stood at $69.75. At Tuesday’s close of $36.28, the stock was trading at a substantial discount to the institutional consensus even before the LB2501 data dropped. That gap is now being repriced in real time.

Slight tangent, but worth flagging: LB2102 was developed under a license agreement with Novartis, signed in November 2023, granting Novartis exclusive worldwide rights to develop and commercialize Legend’s DLL3-targeting CAR-T programs. That structure means investors are not just watching clinical data on LB2102 – they are watching whether Novartis accelerates activity around it.

Key Levels and Risk Considerations

After a 42% single-session move, RSI has pushed to overbought territory near 70. Volume came in well above the 20-day average. The prior 200-day moving average was approximately $25.84. With the stock now trading north of $36, the critical question for traders is whether the EHA full-data presentation on June 14 provides a sustained catalyst or becomes a sell-the-event moment.

• Bull case: EHA full data confirms durability and depth of responses in a larger cohort, accelerating institutional coverage upgrades and attracting partnership interest beyond existing collaborations
• Base case: Stock consolidates in the $30 to $38 range into EHA, with measured buyers accumulating ahead of formal Phase 1 readouts while near-term profit taking creates intraday volatility
• Bear case: Follow-on data at EHA disappoints on durability or shows safety signals at higher doses, triggering a reversal toward the prior support range near $25

The company is still burning cash. Net losses persist. And the in vivo CAR-T data, while compelling, involves 12 patients across two dose levels with a median follow-up of just 2.2 months at DL2. Early data is early data. What traders are pricing is the potential addressable market if LB2501’s profile holds – and in a field where traditional CAR-T requires complex manufacturing and lymphodepletion, an off-the-shelf single-infusion alternative represents a structurally different commercial proposition.

Preparation matters more than conviction here. Watch the EHA session on June 14. Watch volume behavior in the $32 to $34 range as an early signal of institutional participation. And watch how RBC, Morgan Stanley, and the broader sell side respond in the days following full data disclosure.

For informational and educational purposes only. Not investment advice. Trading involves risk, including loss of principal.